Prognosis of patients with BRCA1 -associated ovarian carcinomas depends on TP53 accumulation status in tumor cells
Open Access
- 7 December 2016
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (2) , 369-376
Abstract
No abstract availableKeywords
Funding Information
- Polish Ministry of Science and Higher Education (2 PO5A 068 27)
This publication has 35 references indexed in Scilit:
- BRCA1 and implications for response to chemotherapy in ovarian cancerGynecologic Oncology, 2009
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 MutationsJournal of Clinical Oncology, 2008
- Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian CancerJournal of Clinical Oncology, 2008
- Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changesExperimental Cell Research, 2007
- No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancersGynecologic Oncology, 2004
- Improved survival in women with BRCA‐associated ovarian carcinomaCancer, 2003
- Ovarian Carcinoma In Situ With Germline BRCA1 Mutation and Loss of Heterozygosity at BRCA1 and TP53JNCI: Journal of the National Cancer Institute, 2000
- Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian CancerJAMA, 2000
- Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.Journal of Clinical Oncology, 1998
- Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.Genes & Development, 1997